Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Rodman & Renshaw

Analysts at Rodman & Renshaw initiated coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a research note issued on Thursday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $9.00 price target on the stock. Rodman & Renshaw’s price target would suggest a potential upside of 216.90% from the stock’s current price.

Eupraxia Pharmaceuticals Trading Down 2.0 %

NASDAQ EPRX opened at $2.84 on Thursday. The stock has a fifty day simple moving average of $2.64 and a 200-day simple moving average of $2.68. The stock has a market cap of $77.48 million and a PE ratio of -3.94. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $5.58.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 13,000 shares of the company’s stock, valued at approximately $34,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.